Recombinant human hyaluronidase (rHuPH20)
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for Recombinant human hyaluronidase (rHuPH20), covering 2014-07-11 to 2025-05-23. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]